Arihiko Kanehiro
Okayama University
AirwayInternal medicineChemokineEndocrinologyPathologyReceptorImmunologyAllergyAsthmaInflammationOvalbuminEosinophilEosinophiliaLungBronchoalveolar lavageCytokineAllergic inflammationElastaseMethacholineMedicineBiologyGastroenterology
103Publications
25H-index
1,997Citations
Publications 104
Newest
#1Noriyuki Suzaki (Okayama University)H-Index: 2
#2Akio Hiraki (Okayama University)H-Index: 44
Last. Mitsune TanimotoH-Index: 71
view all 10 authors...
A 71-year-old Japanese man with adenocarcinoma of the lung developed interstitial pneumonia after treatment with paclitaxel. The patient had acute chills and fever on the fourth day after the second exposure to paclitaxel, rapidly got worse despite empiric therapies, and developed prolonged respiratory failure requiring mechanical ventilation. Four months later, he died of respiratory failure due to progression of both interstitial pneumonia and lung cancer. This is the first case developing fat...
Source
#1Atsushi Hirano (Okayama University)H-Index: 8
#2Arihiko Kanehiro (Okayama University)H-Index: 25
Last. Mitsune TanimotoH-Index: 71
view all 11 authors...
We investigated the therapeutic potential of a newly developed antifibrotic agent, pirfenidone, to regulate airway remodeling and the development of allergic airway inflammation and airway hyperresponsiveness after chronic allergen challenge. Administration of pirfenidone after sensitization but during the period of ovalbumin challenge significantly prevented the development of airway hyperresponsiveness and prevented eosinophil and lymphocyte accumulation in the airways. IL-4, IL-5, and IL-13 l...
Source
#1Atsushi Hirano (Okayama University)H-Index: 8
#2Mikio Kataoka (Okayama University)H-Index: 18
Last. Mitsune Tanimoto (Okayama University)H-Index: 71
view all 10 authors...
: We report two patients who were diagnosed with sarcoidosis after receiving interferon (IFN)-α therapy for chronic hepatitis C, and conduct a review the relevant literature. The first patient was a 52-year-old female who developed multiple subcutaneous nodules 2 months after finishing IFN-α therapy. A skin biopsy from subcutaneous nodules on the right elbow joint revealed sarcoid granulomata. These lesions resolved spontaneously 4 months later. The second patient, a 57-year-old male, developed ...
Source
#1Katsuyuki HottaH-Index: 42
#2Katsuyuki KiuraH-Index: 67
Last. Mitsune TanimotoH-Index: 71
view all 17 authors...
Risk factors for the development of interstitial lung disease in patients with non-small cell lung cancer receiving gefitinib and the prognostic factors after interstitial lung disease development have not been established. The aim of this study was to retrospectively identify and evaluate these possible factors. PATIENTS AND METHODS We reviewed the clinical records and radiographs of 365 consecutive patients with non-small cell lung cancer who received gefitinib in West Japan between 2000 and 2...
Source
#1Shigeki Umemura (Okayama University)H-Index: 21
#2Daizo KishinoH-Index: 12
Last. Mitsune Tanimoto (Okayama University)H-Index: 71
view all 11 authors...
We describe a 55-year-old man with advanced adenocarcinoma of the lung who received gefitinib (‘IRESSA’). After gefitinib administration for 7 months, computed tomography scan of the chest demonstrated diffuse ground glass opacity and he was suspected to have developed gefitinib-induced interstitial lung disease (ILD). However, transbronchial lung biopsy (TBLB) revealed tumor cells in the middle-size lung vessels. Afterwards, multiple infarctions of the brain, spleen and left kidney were detecte...
Source
#1Akiko Uchida (Okayama University)H-Index: 7
#2Masahiro TabataH-Index: 35
Last. Mitsune TanimotoH-Index: 71
view all 9 authors...
We describe a case of 63-year-old woman with pulmonary artery sarcoma successfully treated with chemotherapy. She developed acute shortness of breath, and left chest and shoulder pain. Although a diagnosis of acute pulmonary embolism was made at a local hospital and she received anticoagulation and thrombolysis therapy, no improvement was achieved. Thereafter, she underwent a pulmonary thromboectomy in our hospital, and the histological diagnosis was intimal sarcoma of the pulmonary artery. Sinc...
Source
Hepatocyte growth factor (HGF) is known to influence a number of cell types and their production of regulatory cytokines. We investigated the potential of recombinant HGF to regulate not only the development of allergic airway inflammation and airway hyperresponsiveness (AHR), but also airway remodeling in a murine model. Administration of exogenous HGF after sensitization but during ovalbumin challenge significantly prevented AHR, as well as eosinophil and lymphocyte accumulation in the airways...
Source
CD4+ T cells have been shown to play a role in the development of airway hyperresponsivness (AHR) and airway eosinophilia in mice using ablation as well as adoptive transfer experiments. However, as other T cell subsets (CD8, NKT) may play a role in these models, we examined the responses of sensitized CD4-deficient mice after either primary or secondary airway allergen challenge. After sensitization, CD4-deficiency in mice was not associated with airway eosinophilia, allergen-specific IgE, or e...
Source
#1Azzeddine Dakhama (National Jewish Health)H-Index: 54
#2Jung Won ParkH-Index: 39
Last. Erwin W. GelfandH-Index: 117
view all 13 authors...
The mechanisms by which respiratory syncytial virus (RSV) infection causes airway hyperresponsiveness (AHR) are not fully established. We hypothesized that RSV infection may alter the expression of airway sensory neuropeptides, thereby contributing to the development of altered airway function. BALB/c mice were infected with RSV followed by assessment of airway function, inflammation, and sensory neuropeptide expression. After RSV infection, mice developed significant airway inflammation associa...
Source
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.